We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary

Abstract

Get full access to this article

View all access options for this article.

References

Ades

. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105–3124.

Jansen

Crawford

Bergman

. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11: 956–964.

Caldwell

Welton

Ades

. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol 2010; 63: 875–882.

Jansen

Naci

. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013; 11: 159.

Lee

. Review of mixed treatment comparisons in published systematic reviews shows marked increase since 2009. J Clin Epidemiol 2014; 67: 138–143.

Hutchinson

Fox

Havrdova

. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: A systematic review and mixed treatment comparison. Curr Med Res Opin 2014; 30: 613–627.

Fox

Miller

Phillips

. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.